Alendronate Sodium
Product Images NDC 33261-820

10 FDA label images from Aidarex Pharmaceuticals Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alendronate Sodium (NDC 33261-820). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aidarex Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical Structure (Alendronate 70 mg For Teva 1)

Chemical Structure (Alendronate 70 mg For Teva 1)
Chemical structure diagram of Alendronate Sodium showing its bisphosphonate moiety with amino and hydroxyl groups, including associated sodium and water molecules.*
FDA Label Image

Image Label (Alendronate 70 mg For Teva 10)

Image Label (Alendronate 70 mg For Teva 10)
Label for Alendronate Sodium 70 mg tablets, distributed by Aidarex Pharmaceuticals LLC. The label shows a package count of 20 tablets per pack. It includes the NDC 33261-0820-01 and states it is a generic for Fosamax. Manufacturer is Teva Pharmaceuticals USA, Sellersville, PA. Dosage instructions and additional regulatory text are partially visible.*
FDA Label Image

Figure 1 (Alendronate 70 mg For Teva 2)

Figure 1 (Alendronate 70 mg For Teva 2)
A line graph comparing cumulative incidence (%) over time (months) between placebo and alendronate sodium groups. The y-axis shows cumulative incidence up to 10%, and the x-axis spans 0 to 36 months. The graph shows a higher cumulative incidence in the placebo group than the alendronate sodium group over the time period.*
FDA Label Image

Figure 2 (Alendronate 70 mg For Teva 3)

Figure 2 (Alendronate 70 mg For Teva 3)
A bar graph comparing the mean percent increase in Bone Mineral Density (BMD) with standard error (SE) at the lumbar spine, femoral neck, and trochanter between U.S. and multinational groups. The chart shows higher increases for the U.S. group across all three anatomical sites.*
FDA Label Image

Figure 3 (Alendronate 70 mg For Teva 4)

Figure 3 (Alendronate 70 mg For Teva 4)
A line graph from a U.S. study showing mean percent change in Bone Mineral Density (BMD) over 36 months. It compares Alendronate Sodium 10 mg (black circles) versus placebo (white circles), with BMD increasing progressively for Alendronate Sodium and remaining near baseline for placebo.*
FDA Label Image

Figure 3a (Alendronate 70 mg For Teva 5)

Figure 3a (Alendronate 70 mg For Teva 5)
A line graph from a multinational study showing the mean percentage change in bone mineral density (BMD) from baseline over 36 months. It compares Alendronate Sodium 10 mg (solid circles) to placebo (open circles), indicating a steady increase in BMD with Alendronate Sodium and little to no change with placebo.*
FDA Label Image

Figure 4 (Alendronate 70 mg For Teva 6)

Figure 4 (Alendronate 70 mg For Teva 6)
A bar graph titled 'Change in BMD From Baseline 2 Year Study' comparing Alendronate Sodium 5 mg/day with placebo. The graph shows mean percent change in bone mineral density (BMD) with standard error across lumbar spine, femoral neck, trochanter, and total body regions over a 2-year period.*
FDA Label Image

Figure 4a (Alendronate 70 mg For Teva 7)

Figure 4a (Alendronate 70 mg For Teva 7)
A bar chart titled "Change in BMD From Baseline 3 Year Study" comparing mean percentage change in bone mineral density (BMD) plus standard error (SE) at four anatomical sites: Lumbar Spine, Femoral Neck, Trochanter, and Total Body. It contrasts Alendronate Sodium 5 mg/day (white bars) against placebo (striped bars) showing positive change for Alendronate and negative or minimal change for placebo at all sites.*
FDA Label Image

Figure 5 (Alendronate 70 mg For Teva 8)

Figure 5 (Alendronate 70 mg For Teva 8)
A bar chart titled 'Change in BMD From Baseline 2 Year Study' comparing mean percent change in bone mineral density (BMD) plus standard error for Alendronate Sodium 5 mg/day versus placebo. The chart displays results at four anatomical sites: Lumbar Spine, Femoral Neck, Trochanter, and Total Body.*
FDA Label Image

Figure 6 (Alendronate 70 mg For Teva 9)

Figure 6 (Alendronate 70 mg For Teva 9)
A line graph showing mean percent change from baseline in serum alkaline phosphatase levels over 6 months. The graph compares placebo, etidronate 400 mg/day, and alendronate sodium 40 mg/day from both a multinational and U.S. study, with sample sizes indicated for each group. The y-axis represents mean percent change ± standard error, and the x-axis represents time in months.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.